AI
PTGX icon

Atom Investors’s Protagonist Therapeutics PTGX Stock Holding History

Atom Investors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10,338
Closed -$82K – 347
2022
Q2 		$82K Buy
+10,338
New +$125K 0.04% 222
2021
Q2 		– Sell
-30,542
Closed -$791K – 313
2021
Q1 		$791K Sell
30,542
-69,277
-69% -$1.75M 0.13% 124
2020
Q4 		$2.01M Buy
99,819
+88,473
+780% +$1.9M 0.2% 130
2020
Q3 		$222K Buy
+11,346
New +$213K 0.02% 336

Other funds holding PTGX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Atom Investors's PTGX Position: Q3 2022 in Review

Atom Investors sold out of Protagonist Therapeutics (PTGX) in Q3 2022, closing a stake of 10,338 shares — an estimated $82K sold.

Atom Investors first reported a position in PTGX in Q3 2020 and held it in 4 quarters. The position peaked at $2.01M in Q4 2020. 130 funds tracked by Wall St. Rank hold PTGX as of Q3 2022.

  • Atom Investors reported no remaining Protagonist Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Atom Investors sold 10,338 Protagonist Therapeutics shares in Q3 2022, an estimated $82K.
  • Atom Investors first reported a position in Protagonist Therapeutics in Q3 2020 and held it in 4 quarters.
  • Atom Investors's Protagonist Therapeutics position peaked at $2.01M in Q4 2020.
  • 130 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2022.

Based on Atom Investors's 13F filing for Q3 2022, filed 8 Nov 2022.